RVF MP-12

RVF MP-12 is a live attenuated vaccine strain of Rift Valley fever virus (RVFV), developed for the prevention of Rift Valley fever in humans and animals. The vaccine was created by serially passaging the wild-type ZH548 strain of RVFV in human diploid MRC-5 cells in the presence of the chemical mutagen 5-fluorouracil, resulting in 23 mutations across all three viral genome segments (S, M, L) that confer attenuation. These mutations reduce virulence and enhance safety by lowering the risk of reversion to a pathogenic form. The vaccine induces strong neutralizing antibody responses and has demonstrated efficacy and safety in laboratory animals (including rodents and non-human primates) as well as domestic ruminants. In human clinical trials (Phase I/II), it has been shown to be immunogenic and well-tolerated but is not yet approved for general human use; it holds Investigational New Drug status in the US. It is conditionally licensed for veterinary use in some regions[1][4][5][6][7].

Other names

Rift Valley fever virus MP-12Rift Valley Fever Virus Live-Attenuated Vaccine Strain MP-12RVFV MP-12